目的 探讨植入金属裸支架(BMS)治疗急性冠脉综合征(ACS)患者的长期疗效和安全性.方法选择2000—2005年北华大学附属医院住院植入BMS随访资料完整的ACS患者491例为研究对象,均行经皮冠状动脉介入治疗植入BMS.经住院冠状动脉造影随访、门诊随访或电话随访,记录主要终点事件.结果 平均随访(95±39)个月,随访期间累积171例发生主要心脏不良事件(MACE),MACE发生率为34.83%,年均MACE发生率为4.38%.死亡68例(13.85%),靶病变血管重建71例(14.46%),靶血管重建28例(5.70%),晚期支架内血栓(LST)和极晚期支架内血栓(VLST)0例,心力衰竭2例(0.41%),冠状动脉旁路移植2例(0.41%).发生支架内再狭窄106例(21.59%),支架节段内再狭窄60例(12.22%),支架内再狭窄合并支架节段内再狭窄127例(25.87%).结论 植入BMS治疗ACS患者,远期MACE、LST、VLST发生率较低,安全性较好.“,”Objectives To investigate the long-term efficacy and safety of baremetal stent (BMS) implantation in patients with acute coronary syndrome (ACS).Methods A total of 491 ACS patients who underwent BMS implantation at the Affiliated Hospital of Beihua University between 2000 and 2005,for whom complete follow-up data were available,were enrolled in this study.Percutaneous coronary intervention was performed to implant the BMS.The following primary endpoints were recorded by the hospital:coronary angiography follow-up,outpatient follow-up,or telephone follow-up.Results The average follow-up time was (95±39) months.During the follow-up period,there were 171 cases of major cardiac adverse events (MACE). The incidence of MACE was 34.83%,and the average annual MACE rate was 4.38%.There were 68 death cases (13.85%);71 cases (14.46%) of target lesion revascularization;28 cases (5.70%) of target vessel revascularization;0 cases of late stent thrombosis(LST) and very late stent thrombosis(VLST);2 cases (0.41%) of heart failure;and 2 cases (0.41%) of coronary artery bypass graft.In-stent restenosis occurred in 106 cases (21.59%);stent segment restenosis developed in 60 cases (12.22%);and both types of restenosis occurred in 127 cases (25.87%).Conclusion The incidence of MACE, LST and VLST were lower in patients with ACS who underwent BMS implantation;the treatment thus has a favorable safety profile.